Sökning: WFRF:(Lundgren Lotta) > (2010-2014) > A New Look at Drugs...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06909naa a2200541 4500 | |
001 | oai:lup.lub.lu.se:1ccef2f8-3827-47d5-8c53-0a5ce252e901 | |
003 | SwePub | |
008 | 160401s2014 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/42470342 URI |
024 | 7 | a https://doi.org/10.1002/pmic.2013004762 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a for2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Sugihara, Yutakau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-yas |
245 | 1 0 | a A New Look at Drugs Targeting Malignant Melanoma – An Application for Mass Spectrometry Imaging |
264 | c 2014-08-18 | |
264 | 1 | b Wiley,c 2014 |
520 | a Malignant melanoma (MM) patients are being treated with an increasing number of personalized medicine (PM) drugs, several of which are small molecule drugs developed to treat patients with specific disease genotypes and phenotypes. In particular, the clinical application of protein kinase inhibitors (PKI) has been highly effective for certain subsets of MM patients. Vemurafenib, a PKI targeting BRAF mutated protein, has shown significant efficacy in slowing disease progression. In this paper we provide an overview of this new generation of targeted drugs, and demonstrate the first data on localization of personalized medicine drugs within tumor compartments. In this study, we have introduced matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to provide new information on one of the drugs currently used in the PM treatment of MM, vemurafenib. In a proof-of-concept in vitro study, MALDI-MSI was used to identify vemurafenib applied to metastatic lymph nodes tumors of subjects attending the regional hospital network of Southern Sweden. The paper provides evidence of BRAF overexpression in tumors isolated from MM patients and localization of the specific drug targeting BRAF, vemurafenib, using mass spectrometry fragment ion signatures. Our ability to determine drug uptake at the target sites of directed therapy provides important opportunity for increasing our understanding about the mode of action of drug activity within the disease environment. | |
650 | 7 | a TEKNIK OCH TEKNOLOGIERx Medicinteknik0 (SwePub)2062 hsv//swe |
650 | 7 | a ENGINEERING AND TECHNOLOGYx Medical Engineering0 (SwePub)2062 hsv//eng |
653 | a Clinical studies | |
653 | a Genes | |
653 | a Malignant melanoma | |
653 | a Personalized medicine | |
653 | a Protein sequencing | |
653 | a Proteomics | |
653 | a Mass spectrometry imaging | |
700 | 1 | a Végvári, Ákosu Lund University,Lunds universitet,Avdelningen för Biomedicinsk teknik,Institutionen för biomedicinsk teknik,Institutioner vid LTH,Lunds Tekniska Högskola,Department of Biomedical Engineering,Departments at LTH,Faculty of Engineering, LTH4 aut0 (Swepub:lu)elma-asv |
700 | 1 | a Welinder, Charlotteu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-cbr |
700 | 1 | a Jönsson, Göran Bu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-gjo |
700 | 1 | a Ingvar, Christianu Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kir-cin |
700 | 1 | a Lundgren, Lottau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-ilu |
700 | 1 | a Olsson, Håkanu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-hol |
700 | 1 | a Breslin, Thomasu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)thep-tbr |
700 | 1 | a Wieslander, Elisabetu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-etw |
700 | 1 | a Laurell, Thomasu Lund University,Lunds universitet,Avdelningen för Biomedicinsk teknik,Institutionen för biomedicinsk teknik,Institutioner vid LTH,Lunds Tekniska Högskola,Department of Biomedical Engineering,Departments at LTH,Faculty of Engineering, LTH4 aut0 (Swepub:lu)elma-tla |
700 | 1 | a Rezeli, Melindau Lund University,Lunds universitet,Avdelningen för Biomedicinsk teknik,Institutionen för biomedicinsk teknik,Institutioner vid LTH,Lunds Tekniska Högskola,Department of Biomedical Engineering,Departments at LTH,Faculty of Engineering, LTH4 aut0 (Swepub:lu)elma-mrl |
700 | 1 | a Jansson, Bo4 aut |
700 | 1 | a Fehniger, Thomasu Lund University,Lunds universitet,Avdelningen för Biomedicinsk teknik,Institutionen för biomedicinsk teknik,Institutioner vid LTH,Lunds Tekniska Högskola,Department of Biomedical Engineering,Departments at LTH,Faculty of Engineering, LTH4 aut0 (Swepub:lu)elma-tfr |
700 | 1 | a Baldetorp, Bou Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-bba |
700 | 1 | a Marko-Varga, Györgyu Lund University,Lunds universitet,Avdelningen för Biomedicinsk teknik,Institutionen för biomedicinsk teknik,Institutioner vid LTH,Lunds Tekniska Högskola,Department of Biomedical Engineering,Departments at LTH,Faculty of Engineering, LTH4 aut0 (Swepub:lu)akem-gmv |
710 | 2 | a Tumörmikromiljöb Sektion I4 org |
773 | 0 | t Proteomicsd : Wileyg 14:17-18, s. 1963-1970q 14:17-18<1963-1970x 1615-9861x 1615-9853 |
856 | 4 | u http://dx.doi.org/10.1002/pmic.201300476x freey FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/4247034 |
856 | 4 8 | u https://doi.org/10.1002/pmic.201300476 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy